2026 Q1 -tulosraportti
57 päivää sitten
‧29 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·1 t sitten · MuokattuBioporto: That precisely summarizes the situation for the Danish diagnostics company BioPorto, which for over a decade has fought to get their groundbreaking NGAL kidney test (ProNephro AKI) fully approved in the lucrative American market. For investors, the stock is considered the ultimate binary "lottery ticket", where the company's long-term survival and success truly depend on the final FDA approval for adults.The story behind the lengthy process and the current status of the investment case can be divided into the following points:Status of FDA approvalPediatric approval secured: BioPorto received a historic FDA 510(k) approval for children and adolescents (between 3 months and 21 years) at the end of 2023. Sales thereof are being rolled out via partnerships with giants like Roche Diagnostics.The adult market is the goal: However, the pediatric market is commercially limited. The entire great potential lies in getting the test approved for adults, as acute kidney injuries (AKI) are far more common in critically ill adults in intensive care units.The timeline slipped: BioPorto had to postpone the expected FDA approval from the end of 2025 to 2027. The company submitted a so-called pre-submission to the FDA in spring 2026 to fine-tune the study's design and expects to submit the final application before the end of 2026.The bottom line for investorsInvestors looking at BioPorto right now face a binary scenario:If approval succeeds (2027): The company can transform itself from a loss-making biotech company into a profitable business with a multiplied top line.If approval fails or is postponed again: The company will likely run out of money, and the case will suffer a potential death blow, as current liquid funds primarily suffice to cover strategic expenses through 2026
Thanks Born1956, but I won't hide that it's disappointing that they haven't mentioned KDIGO's strong recommendations, which will give the NGAL test a proper push out into the world when documents are finalized, and that CLIA, see link, will ensure that the large hospitals in the USA can still purchase the NGAL test for adults, while the FDA is in the process of investigating whether the test for adults will be approved in the USA. There are more than 400 large hospitals in the USA that can use CLIA, and these also own smaller hospitals, where the large hospitals will run tests for the smaller ones with the NGAL test. Only public hospitals have to wait for the NGAL test to be approved by the FDA. I can't help but wonder why this article was written when what they write is not updated. https://pubmed.ncbi.nlm.nih.gov/2253342/- ·5 t sittenBørsen has an article with Bioporto today, but I don't have a subscription, but is that why the stock is rising today?
Is there really no one who has read the article and can give a short summary. Is it just a summary of what we already know, that they have spent a long time and a lot of money on hopes and expectations for an FDA approval for adults, or are there actually some stock analysts giving an estimate of where the stock is going - up or completely down, - ·8.7. · MuokattuDNB Carnegie Access: BioPorto: Awaiting a decision on KDIGO – H1 preview About DNB Carnegie DNB Carnegie is the leading and independent Nordic investment and private bank. Our activities within Corporate Finance, Securities and Research, Private Banking and Wealth Management are among the market leaders within their respective sectors. Together they build an unparalleled combination of integrated knowledge that guides our clients to better business. DNB Carnegie operates in six countries and has more than 800 employees. https://access.dnbcarnegie.com/publication/1dff5a19-3381-40d2-928c-08de95edec98https://access.dnbcarnegie.com/companies/1630It is a very interesting stock in the long term. If I have understood correctly, they earn 0 kr. they are in phase 2 and everything can go wrong. they have just had an emission and there are probably more on the way. I will wait, just before they start to make money, and it may take some years before that happens. Thanks for the attention, I will put it on my watchlist.
- ·7.7.Urinary neutrophil gelatinase-associated lipocalin as an early and reliable biomarker for diabetic nephropathy in type 2 diabetes mellitus https://pubmed.ncbi.nlm.nih.gov/42099535/
·1.7.1 juli 2026 Newsletter Dear Shareholder, As we move through 2026, we are pleased to share an update on BioPorto's continued development and strategic progress. The first half of the year has been characterized by disciplined execution, important clinical and regulatory progress, and a sharper organizational focus on our core mission; improving kidney health and patient outcomes. Since the beginning of the year, our work has been guided by our "Forward" strategy and our ambition to establish NGAL as a standard-of-care biomarker in relation to acute kidney injury (AKI). The "Forward" strategy was announced in November 2025 and focused on creating market access and commercializing the biomarker that BioPorto has developed. Progress in the U.S. market The U.S. remains a key priority for BioPorto and an important growth opportunity from both a market access and commercial point of view. In the first half of 2026, we reported preliminary results from our adult NGAL cutoff study, which supported the clinical value of NGAL in identifying patients at risk for AKI. Following interactions with the U.S. Food and Drug Administration (FDA), we will initiate the validation study in the adult segment. All with a focus on gaining access to the much larger adult portion of the market. At the same time, we continue to build our commercial understanding through increased adoption of NGAL in the research-use-only (RUO) segment. We are following our plan to have more than 60 U.S. university hospitals by the end of 2026. Clinical and Scientific Developments The broader clinical environment around AKI continues to evolve positively. The recently published draft of the updated KDIGO guidelines highlights a continued shift towards biomarker-driven diagnostic methods and improved clinical decision-making. The final KDIGO guidelines are expected to be published towards the end of the year. We see this development as support for BioPorto's NGAL platform and believe that it can help increase awareness and support the long-term use of biomarker-based diagnostics – such as the company's biomarker – and thereby support long-term value creation for our shareholders. Building a Scalable Organization Preparing the company for growth remains a key priority. During 2026, we completed the relocation of R&D activities from the U.S. to Denmark and strengthened capabilities in project management, design control, and research through targeted hirings. These investments help create a stronger and more scalable organization for the future. We continued to strengthen the company's operational foundation through improved processes, quality systems, and compliance practices. The voluntary recall, announced in June 2026, should be seen in this context. It was a proactive and responsible action that reflected our commitment to high standards of product quality and patient safety and thereby supported long-term value creation for our shareholders. Our "Forward" Strategy and Focused Execution In April, we completed the divestment of our antibody business. This refined our strategic focus and strengthened our financial flexibility. By divesting a non-core activity, we focused our capital and organizational resources on the "Forward" strategy. We remain committed to disciplined execution in relation to our strategic long-term ambitions: - Revenue growth as NGAL adoption increases; deliver revenue in 2028 of DKK 135-185 million - Leverage the advantage of scalability; deliver an EBITDA margin of at least 15 % in 2028 - Create sustainability; deliver positive cash flow break-even in the second half of 2028 We welcome and greatly appreciate the continued trust and support from our shareholders and value the ongoing dialogue we have with you. We look forward to updating you further as we move through what we expect will be an important and milestone-rich period for BioPorto. I wish you all a wonderful summer. Carsten Buhl, CEO
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
57 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sitten · MuokattuBioporto: That precisely summarizes the situation for the Danish diagnostics company BioPorto, which for over a decade has fought to get their groundbreaking NGAL kidney test (ProNephro AKI) fully approved in the lucrative American market. For investors, the stock is considered the ultimate binary "lottery ticket", where the company's long-term survival and success truly depend on the final FDA approval for adults.The story behind the lengthy process and the current status of the investment case can be divided into the following points:Status of FDA approvalPediatric approval secured: BioPorto received a historic FDA 510(k) approval for children and adolescents (between 3 months and 21 years) at the end of 2023. Sales thereof are being rolled out via partnerships with giants like Roche Diagnostics.The adult market is the goal: However, the pediatric market is commercially limited. The entire great potential lies in getting the test approved for adults, as acute kidney injuries (AKI) are far more common in critically ill adults in intensive care units.The timeline slipped: BioPorto had to postpone the expected FDA approval from the end of 2025 to 2027. The company submitted a so-called pre-submission to the FDA in spring 2026 to fine-tune the study's design and expects to submit the final application before the end of 2026.The bottom line for investorsInvestors looking at BioPorto right now face a binary scenario:If approval succeeds (2027): The company can transform itself from a loss-making biotech company into a profitable business with a multiplied top line.If approval fails or is postponed again: The company will likely run out of money, and the case will suffer a potential death blow, as current liquid funds primarily suffice to cover strategic expenses through 2026Thanks Born1956, but I won't hide that it's disappointing that they haven't mentioned KDIGO's strong recommendations, which will give the NGAL test a proper push out into the world when documents are finalized, and that CLIA, see link, will ensure that the large hospitals in the USA can still purchase the NGAL test for adults, while the FDA is in the process of investigating whether the test for adults will be approved in the USA. There are more than 400 large hospitals in the USA that can use CLIA, and these also own smaller hospitals, where the large hospitals will run tests for the smaller ones with the NGAL test. Only public hospitals have to wait for the NGAL test to be approved by the FDA. I can't help but wonder why this article was written when what they write is not updated. https://pubmed.ncbi.nlm.nih.gov/2253342/
- ·5 t sittenBørsen has an article with Bioporto today, but I don't have a subscription, but is that why the stock is rising today?Is there really no one who has read the article and can give a short summary. Is it just a summary of what we already know, that they have spent a long time and a lot of money on hopes and expectations for an FDA approval for adults, or are there actually some stock analysts giving an estimate of where the stock is going - up or completely down,
- ·8.7. · MuokattuDNB Carnegie Access: BioPorto: Awaiting a decision on KDIGO – H1 preview About DNB Carnegie DNB Carnegie is the leading and independent Nordic investment and private bank. Our activities within Corporate Finance, Securities and Research, Private Banking and Wealth Management are among the market leaders within their respective sectors. Together they build an unparalleled combination of integrated knowledge that guides our clients to better business. DNB Carnegie operates in six countries and has more than 800 employees. https://access.dnbcarnegie.com/publication/1dff5a19-3381-40d2-928c-08de95edec98https://access.dnbcarnegie.com/companies/1630It is a very interesting stock in the long term. If I have understood correctly, they earn 0 kr. they are in phase 2 and everything can go wrong. they have just had an emission and there are probably more on the way. I will wait, just before they start to make money, and it may take some years before that happens. Thanks for the attention, I will put it on my watchlist.
- ·7.7.Urinary neutrophil gelatinase-associated lipocalin as an early and reliable biomarker for diabetic nephropathy in type 2 diabetes mellitus https://pubmed.ncbi.nlm.nih.gov/42099535/
- ·1.7.1 juli 2026 Newsletter Dear Shareholder, As we move through 2026, we are pleased to share an update on BioPorto's continued development and strategic progress. The first half of the year has been characterized by disciplined execution, important clinical and regulatory progress, and a sharper organizational focus on our core mission; improving kidney health and patient outcomes. Since the beginning of the year, our work has been guided by our "Forward" strategy and our ambition to establish NGAL as a standard-of-care biomarker in relation to acute kidney injury (AKI). The "Forward" strategy was announced in November 2025 and focused on creating market access and commercializing the biomarker that BioPorto has developed. Progress in the U.S. market The U.S. remains a key priority for BioPorto and an important growth opportunity from both a market access and commercial point of view. In the first half of 2026, we reported preliminary results from our adult NGAL cutoff study, which supported the clinical value of NGAL in identifying patients at risk for AKI. Following interactions with the U.S. Food and Drug Administration (FDA), we will initiate the validation study in the adult segment. All with a focus on gaining access to the much larger adult portion of the market. At the same time, we continue to build our commercial understanding through increased adoption of NGAL in the research-use-only (RUO) segment. We are following our plan to have more than 60 U.S. university hospitals by the end of 2026. Clinical and Scientific Developments The broader clinical environment around AKI continues to evolve positively. The recently published draft of the updated KDIGO guidelines highlights a continued shift towards biomarker-driven diagnostic methods and improved clinical decision-making. The final KDIGO guidelines are expected to be published towards the end of the year. We see this development as support for BioPorto's NGAL platform and believe that it can help increase awareness and support the long-term use of biomarker-based diagnostics – such as the company's biomarker – and thereby support long-term value creation for our shareholders. Building a Scalable Organization Preparing the company for growth remains a key priority. During 2026, we completed the relocation of R&D activities from the U.S. to Denmark and strengthened capabilities in project management, design control, and research through targeted hirings. These investments help create a stronger and more scalable organization for the future. We continued to strengthen the company's operational foundation through improved processes, quality systems, and compliance practices. The voluntary recall, announced in June 2026, should be seen in this context. It was a proactive and responsible action that reflected our commitment to high standards of product quality and patient safety and thereby supported long-term value creation for our shareholders. Our "Forward" Strategy and Focused Execution In April, we completed the divestment of our antibody business. This refined our strategic focus and strengthened our financial flexibility. By divesting a non-core activity, we focused our capital and organizational resources on the "Forward" strategy. We remain committed to disciplined execution in relation to our strategic long-term ambitions: - Revenue growth as NGAL adoption increases; deliver revenue in 2028 of DKK 135-185 million - Leverage the advantage of scalability; deliver an EBITDA margin of at least 15 % in 2028 - Create sustainability; deliver positive cash flow break-even in the second half of 2028 We welcome and greatly appreciate the continued trust and support from our shareholders and value the ongoing dialogue we have with you. We look forward to updating you further as we move through what we expect will be an important and milestone-rich period for BioPorto. I wish you all a wonderful summer. Carsten Buhl, CEO
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
57 päivää sitten
‧29 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 26.3. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 15.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·1 t sitten · MuokattuBioporto: That precisely summarizes the situation for the Danish diagnostics company BioPorto, which for over a decade has fought to get their groundbreaking NGAL kidney test (ProNephro AKI) fully approved in the lucrative American market. For investors, the stock is considered the ultimate binary "lottery ticket", where the company's long-term survival and success truly depend on the final FDA approval for adults.The story behind the lengthy process and the current status of the investment case can be divided into the following points:Status of FDA approvalPediatric approval secured: BioPorto received a historic FDA 510(k) approval for children and adolescents (between 3 months and 21 years) at the end of 2023. Sales thereof are being rolled out via partnerships with giants like Roche Diagnostics.The adult market is the goal: However, the pediatric market is commercially limited. The entire great potential lies in getting the test approved for adults, as acute kidney injuries (AKI) are far more common in critically ill adults in intensive care units.The timeline slipped: BioPorto had to postpone the expected FDA approval from the end of 2025 to 2027. The company submitted a so-called pre-submission to the FDA in spring 2026 to fine-tune the study's design and expects to submit the final application before the end of 2026.The bottom line for investorsInvestors looking at BioPorto right now face a binary scenario:If approval succeeds (2027): The company can transform itself from a loss-making biotech company into a profitable business with a multiplied top line.If approval fails or is postponed again: The company will likely run out of money, and the case will suffer a potential death blow, as current liquid funds primarily suffice to cover strategic expenses through 2026Thanks Born1956, but I won't hide that it's disappointing that they haven't mentioned KDIGO's strong recommendations, which will give the NGAL test a proper push out into the world when documents are finalized, and that CLIA, see link, will ensure that the large hospitals in the USA can still purchase the NGAL test for adults, while the FDA is in the process of investigating whether the test for adults will be approved in the USA. There are more than 400 large hospitals in the USA that can use CLIA, and these also own smaller hospitals, where the large hospitals will run tests for the smaller ones with the NGAL test. Only public hospitals have to wait for the NGAL test to be approved by the FDA. I can't help but wonder why this article was written when what they write is not updated. https://pubmed.ncbi.nlm.nih.gov/2253342/
- ·5 t sittenBørsen has an article with Bioporto today, but I don't have a subscription, but is that why the stock is rising today?Is there really no one who has read the article and can give a short summary. Is it just a summary of what we already know, that they have spent a long time and a lot of money on hopes and expectations for an FDA approval for adults, or are there actually some stock analysts giving an estimate of where the stock is going - up or completely down,
- ·8.7. · MuokattuDNB Carnegie Access: BioPorto: Awaiting a decision on KDIGO – H1 preview About DNB Carnegie DNB Carnegie is the leading and independent Nordic investment and private bank. Our activities within Corporate Finance, Securities and Research, Private Banking and Wealth Management are among the market leaders within their respective sectors. Together they build an unparalleled combination of integrated knowledge that guides our clients to better business. DNB Carnegie operates in six countries and has more than 800 employees. https://access.dnbcarnegie.com/publication/1dff5a19-3381-40d2-928c-08de95edec98https://access.dnbcarnegie.com/companies/1630It is a very interesting stock in the long term. If I have understood correctly, they earn 0 kr. they are in phase 2 and everything can go wrong. they have just had an emission and there are probably more on the way. I will wait, just before they start to make money, and it may take some years before that happens. Thanks for the attention, I will put it on my watchlist.
- ·7.7.Urinary neutrophil gelatinase-associated lipocalin as an early and reliable biomarker for diabetic nephropathy in type 2 diabetes mellitus https://pubmed.ncbi.nlm.nih.gov/42099535/
- ·1.7.1 juli 2026 Newsletter Dear Shareholder, As we move through 2026, we are pleased to share an update on BioPorto's continued development and strategic progress. The first half of the year has been characterized by disciplined execution, important clinical and regulatory progress, and a sharper organizational focus on our core mission; improving kidney health and patient outcomes. Since the beginning of the year, our work has been guided by our "Forward" strategy and our ambition to establish NGAL as a standard-of-care biomarker in relation to acute kidney injury (AKI). The "Forward" strategy was announced in November 2025 and focused on creating market access and commercializing the biomarker that BioPorto has developed. Progress in the U.S. market The U.S. remains a key priority for BioPorto and an important growth opportunity from both a market access and commercial point of view. In the first half of 2026, we reported preliminary results from our adult NGAL cutoff study, which supported the clinical value of NGAL in identifying patients at risk for AKI. Following interactions with the U.S. Food and Drug Administration (FDA), we will initiate the validation study in the adult segment. All with a focus on gaining access to the much larger adult portion of the market. At the same time, we continue to build our commercial understanding through increased adoption of NGAL in the research-use-only (RUO) segment. We are following our plan to have more than 60 U.S. university hospitals by the end of 2026. Clinical and Scientific Developments The broader clinical environment around AKI continues to evolve positively. The recently published draft of the updated KDIGO guidelines highlights a continued shift towards biomarker-driven diagnostic methods and improved clinical decision-making. The final KDIGO guidelines are expected to be published towards the end of the year. We see this development as support for BioPorto's NGAL platform and believe that it can help increase awareness and support the long-term use of biomarker-based diagnostics – such as the company's biomarker – and thereby support long-term value creation for our shareholders. Building a Scalable Organization Preparing the company for growth remains a key priority. During 2026, we completed the relocation of R&D activities from the U.S. to Denmark and strengthened capabilities in project management, design control, and research through targeted hirings. These investments help create a stronger and more scalable organization for the future. We continued to strengthen the company's operational foundation through improved processes, quality systems, and compliance practices. The voluntary recall, announced in June 2026, should be seen in this context. It was a proactive and responsible action that reflected our commitment to high standards of product quality and patient safety and thereby supported long-term value creation for our shareholders. Our "Forward" Strategy and Focused Execution In April, we completed the divestment of our antibody business. This refined our strategic focus and strengthened our financial flexibility. By divesting a non-core activity, we focused our capital and organizational resources on the "Forward" strategy. We remain committed to disciplined execution in relation to our strategic long-term ambitions: - Revenue growth as NGAL adoption increases; deliver revenue in 2028 of DKK 135-185 million - Leverage the advantage of scalability; deliver an EBITDA margin of at least 15 % in 2028 - Create sustainability; deliver positive cash flow break-even in the second half of 2028 We welcome and greatly appreciate the continued trust and support from our shareholders and value the ongoing dialogue we have with you. We look forward to updating you further as we move through what we expect will be an important and milestone-rich period for BioPorto. I wish you all a wonderful summer. Carsten Buhl, CEO
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt